Legal status · reviewed 20 August 2026

Is compounded tirzepatide still legal?

The two routes, and what each one requires

Compounded medication reaches a patient down one of two paths, and they are not interchangeable.

Section 503A is a state-licensed pharmacy compounding for one named patient against that patient’s own prescription. It still exists. But a 503A pharmacy may not make what the statute calls a product that is essentially a copy of a commercially available drug — the same active ingredient, a strength within roughly ten percent, given the same way — unless the prescriber determines and documents that this particular patient needs something significantly different. A documented allergy to an inactive ingredient in the branded pen is FDA’s own example. A checkbox on a telehealth intake form is not that determination.

Section 503B is a registered outsourcing facility compounding at scale, without individual prescriptions. It may only use a bulk substance if that substance sits on FDA’s 503B bulks list, or if the drug is in shortage. Tirzepatide is neither. There is no 503B route to compounded tirzepatide today.

The four-prescription rule almost nobody mentions

Here is the part missing from most coverage of this question. FDA has said it does not currently intend to act against a 503A pharmacy for compounding what is essentially a copy — even with no documented clinical difference — so long as that pharmacy fills four or fewer prescriptions of that specific product in a calendar month.

Read that against how compounded tirzepatide is actually sold. A telehealth program shipping monthly refills to thousands of subscribers is not filling four prescriptions a month. A seller operating at that scale is therefore relying either on genuine, individually documented clinical need for every patient, or on something else. That is worth asking about before starting — and it is a question about the seller, not about the drug.

It also matters that this is enforcement discretion: a statement about what FDA intends to pursue, not a legal exception. It can be withdrawn without anything in the law changing.

Adding B12 does not make it a different drug

Many sellers describe their product as a personalized or combination formulation — most often tirzepatide with vitamin B12 — and offer that as the reason it may be compounded. FDA addressed this directly in its April 2026 update: a GLP-1 combined with B12 is still treated as essentially a copy where the active ingredient is given the same way at a strength within ten percent of the approved product, unless there is documented, patient-specific clinical justification for the addition.

The same reasoning applies to a non-standard strength chosen so that it does not match a commercial dose. What matters is whether an individual patient needed it, not whether the number on the vial is unusual.

What your state adds on top

Federal rules are the floor, and a state can be stricter. Since 2023 Mississippi’s medical board has barred physicians from prescribing, dispensing or administering compounded semaglutide outright — on a state rule about off-label weight-loss use, unrelated to federal shortage status. Nevada’s pharmacy board issued its own enforcement notice to compounders in June 2025. Alabama’s medical board has ruled on sourcing standards.

We found no state that has independently banned compounded tirzepatide by statute — but we did not run an exhaustive fifty-state sweep, and we will not imply that we did. Where a seller says it ships to your state, that is the seller’s own claim about its own operations, and what each one says, by state, is here.

What to ask a seller

• Which route are you compounding under — 503A patient-specific, or something else?
• What clinical reason will be documented for me specifically, and by whom?
• Which pharmacy fills it, and is it licensed in my state?
• What happens to my prescription if FDA finalizes the 503B proposal, or if the Fifth Circuit rules?

A seller that answers these plainly is telling you something. So is one that does not.

Timeline

Every row links the document it came from, not a report about it.

1. 15 Dec 2022Tirzepatide injection is added to FDA's drug shortage list. The shortage is what makes broad compounding possible at all. FDA drug shortage database
2. 2 Oct 2024FDA first determines the shortage resolved and removes tirzepatide from the list. recited in FDA's declaratory order
3. 7 Oct 2024The Outsourcing Facilities Association and a compounder sue FDA over that determination in the Northern District of Texas. docket, 4:24-cv-00953
4. 11 Oct 2024On FDA's own motion the court sends the decision back to the agency to be reconsidered, and the October determination is withdrawn. declaratory order, note 2
5. 19 Dec 2024FDA issues a declaratory order re-determining that the shortage is resolved, and sets the off-ramps: 60 days for 503A pharmacies, 90 days for 503B outsourcing facilities. FDA declaratory order
6. 5 Mar 2025The court declines to pause FDA's decision while the case runs. The deadlines hold. FDA statement log
7. 10 Mar 2025FDA confirms the 503A off-ramp for tirzepatide has closed. FDA statement log
8. 19 Mar 2025The 503B off-ramp closes. From here an outsourcing facility has no route to bulk tirzepatide at all. FDA statement log
9. 13 May 2025The district court rules for FDA on the merits and the case is terminated at that level. The compounders appeal to the Fifth Circuit. docket, 4:24-cv-00953
10. 30 Mar 2026The Fifth Circuit hears argument in the consolidated appeal. No ruling has been published. appeal No. 25-10758
11. 1 May 2026FDA formally proposes that semaglutide, tirzepatide and liraglutide never be added to the 503B bulks list. A proposal, not a rule. 91 FR 23431, docket FDA-2018-N-3240
12. 26 Jun 2026FDA extends the comment period on that proposal by thirty days. 91 FR 38719
13. 30 Jul 2026The extended comment period closes. As of this page's review date no final determination has been published. 91 FR 38719

What we could not verify

The Fifth Circuit had published no ruling in the consolidated appeal when this page was last reviewed, and we could not reach the court docket directly to confirm that beyond the reported argument date — so read “pending” as the best-supported status rather than a confirmed absence. The district court’s merits opinion of May 2025 is dated here from the docket record rather than from the opinion itself, and the March 2025 order declining to pause the decision is reported as sealed. We have not confirmed whether tirzepatide was ever formally nominated for the 503B bulks list before this proposal, only that it has never been on it.

Informational only. This is not legal advice and not medical advice, and it describes the federal position rather than any individual seller’s compliance with it — which a price index cannot determine and does not claim to.